SH
Publicaties op Oncologisch.com
Gut Microbiota in Gevorderd NSCLC Receiving Chemoimmunotherapy: An Ancillary Biomarker Study From the Fase III Trial ...
Gerandomiseerde Fase III Study of EGFR Tyrosine Kinase Inhibitor and Intercalated Platinum-Doublet Chemotherapy for N...
Nivolumab versus carboplatine-pemetrexed bij EGFR-gemuteerd NSCLC na TKI: fase II
Osimertinib plus bevacizumab versus osimertinib bij T790M NSCLC